1月,登《Journal of Experimental & Clinical Cancer Research》(IF:11.161);
2月,再登《Clinical and Translational Medicine》(IF:11.492);
3月,又登《Journal of Experimental & Clinical Cancer Research》(IF:11.161);
連續(xù)3個(gè)月都發(fā)表影響因子10+的高水平文章,充分展現(xiàn)了南京中醫(yī)藥大學(xué)楊燁和顧春艷教授團(tuán)隊(duì)強(qiáng)大的科研實(shí)力。
值得一提的是,在這些研究中,該團(tuán)隊(duì)都選擇了翌圣的轉(zhuǎn)染試劑產(chǎn)品用于相關(guān)基因的細(xì)胞轉(zhuǎn)染:
[1] Liu R, Yang J, et al. Optogenetic control of RNA function and metabolism using engineered light-switchable RNA-binding proteins. Nat Biotechnol. 2022 Jan 3. (IF:55)華東理工大學(xué)生物工程學(xué)院楊弋團(tuán)隊(duì)
[2] Zhou J, Chen P, et al. Cas12a variants designed for lower genome-wide off-target effect through stringent PAM recognition. Mol Ther. 2022 Jan 5.(IF:11.454)武漢大學(xué)生命科學(xué)學(xué)院殷雷團(tuán)隊(duì)
[3] Chen S, Cao X, et al. circVAMP3 Drives CAPRIN1 Phase Separation and Inhibits Hepatocellular Carcinoma by Suppressing c-Myc Translation. Adv Sci (Weinh). 2022 Jan 24.(IF:16.808)中國(guó)科學(xué)院北京生命科學(xué)研究院趙方慶團(tuán)隊(duì)
[4] Gu C, Wang Y, et al. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. J Exp Clin Cancer Res. 2022 Jan 6.(11.161)南京中醫(yī)藥大學(xué)楊燁顧春艷團(tuán)隊(duì)[6] Qin J, Cai Y, et al. Molecular mechanism of agonism and inverse agonism in ghrelin receptor. Nat Commun. 2022 Jan 13.(14.9)四川大學(xué)生物治療國(guó)家重點(diǎn)實(shí)驗(yàn)室邵振華團(tuán)隊(duì)
[7] Tang X, Deng Z, et al. A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing. J Exp Clin Cancer Res. 2022 Mar 8.(11.161)南京中醫(yī)藥大學(xué)楊燁顧春艷團(tuán)隊(duì)
[8] Xie F, Su P, et al. Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID-19 Therapy. Adv Mater. 2021 Oct 19. (IF:30.849)蘇州大學(xué)生物醫(yī)學(xué)研究院周芳芳團(tuán)隊(duì)和浙江大學(xué)生命科學(xué)研究院張龍團(tuán)隊(duì)
產(chǎn)品描述
產(chǎn)品特點(diǎn)
高效性:適合瞬時(shí)轉(zhuǎn)染或者穩(wěn)定轉(zhuǎn)染細(xì)胞系。
低毒性:轉(zhuǎn)染細(xì)胞保持很好的活性。
適應(yīng)性廣:普通細(xì)胞、難轉(zhuǎn)染的原代細(xì)胞、活體全面覆蓋。
操作簡(jiǎn)便:適合血清存在的培養(yǎng)基,轉(zhuǎn)染前后無需更換培養(yǎng)基。
性價(jià)比高:經(jīng)濟(jì)實(shí)用,轉(zhuǎn)染效率高,價(jià)格低
數(shù)據(jù)展示
應(yīng)用場(chǎng)景 |
名稱 |
貨號(hào) |
規(guī)格 |
細(xì)胞類型:貼壁/懸浮 核酸類型:DNA、siRNA |
40802ES02 |
0.5 mL |
|
40802ES03 |
1.0 mL |
||
40802ES08 |
5×1 mL |
||
細(xì)胞類型:貼壁/懸浮 |
40803ES70 |
200 T |
|
用途:病毒感染、DNA轉(zhuǎn)染 |
40804ES76 |
500 μL |
|
40804ES86 |
5×500 μL |
||
細(xì)胞類型:懸浮 |
40805ES02 |
0.5 mL |
|
40805ES03 |
1.0 mL |
||
40805ES08 |
5×1 mL |
||
細(xì)胞類型:貼壁/懸浮 |
40806ES01 |
0.1 mL |
|
40806ES02 |
0.5 mL |
||
40806ES03 |
1.0 mL |
||
細(xì)胞類型:貼壁/懸浮 |
40808ES02 |
0.5 mL |
|
40808ES03 |
1 mL |
||
40808ES08 |
5×1 mL |
||
細(xì)胞類型:貼壁/懸浮 |
40809ES01 |
0.1 mL |
|
40809ES03 |
1 mL |
||
細(xì)胞類型:貼壁/懸浮 |
40815ES03 |
1 g |
|
40815ES08 |
5×1 g |
||
細(xì)胞類型:貼壁/懸浮 |
40816ES02 |
100 mg |
|
40816ES03 |
1 g |
||
細(xì)胞類型:293 |
40820ES04 |
1.5 mL |
|
40820ES10 |
10 mL |
||
40820ES60 |
100 mL |
||
細(xì)胞類型:293 核酸類型:DNA 用途:AAV/LV載體大規(guī)模生產(chǎn) |
40821ES10 |
10 mL |
|
40821ES60 |
100 mL |
||
40821ES80 |
1 L |